Compare CBAT & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBAT | TVGN |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Blank Checks |
| Sector | Miscellaneous | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.1M | 63.9M |
| IPO Year | 2006 | N/A |
| Metric | CBAT | TVGN |
|---|---|---|
| Price | $0.79 | $7.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 79.2K | 14.6K |
| Earning Date | 05-18-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $195,189,306.00 | N/A |
| Revenue This Year | $66.88 | N/A |
| Revenue Next Year | $41.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.52 | N/A |
| 52 Week Low | $0.77 | $0.14 |
| 52 Week High | $1.25 | $10.76 |
| Indicator | CBAT | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 54.51 |
| Support Level | $0.78 | $0.47 |
| Resistance Level | $0.93 | $9.40 |
| Average True Range (ATR) | 0.03 | 0.63 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 16.67 | 23.08 |
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments; CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe, India, Africa, and other regions.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.